immunology research and reports

Aims and scope

Immunologic Research represents a unique medium for the presentation, discussion and clarification of complex scientific data. The scope of the journal covers the entire spectrum of immunology from the molecular and cellular level to immunological diseases and clinical applications. By maintaining a balance between basic and clinical data Immunologic Research provides a platform for researchers, clinicians as well as experts from industry to bring laboratory findings into the clinics. Our journal also provides a platform to present historical reviews and landmark discoveries as well as to discuss novel measure to teach immunology during public events and in the class room. Submissions are welcomed in the form of original articles, reviews, brief communications, case reports, comments about recent findings reported in other journals and letters to the editor. Editorials, guidelines and new techniques of innovative importance are also encouraged. All submissions will be subjected to peer-review by independent reviewers and members of the Editorial Board. The scientific quality will be monitored and maintained by a Board of Editors with expertise in a broad spectrum of immunological subspecialties.

• Find a journal
• Publish with us
• Track your research

Report: COVID-19 immunology research

ISSN: 2754-5016 | Open Access

Journal of immunology research & reports, journal home.

• Impact Factor 0.5*
• Citations Value 84.5%
• Acceptance Rate 90%
• Associated Conference

Q4- H indexed

Journal of Immunology Research & Reports is an open access peer-reviewed journal from the publishers of Scientific Research and Community (SRC) which publishes articles in the form of written, video and power-point presentations from the arena of Immunology Research & Reports. The journal focuses to build up accessing the complete content of articles freely from online for reader’s perusal.

Article acceptance will be in the form of Research, Review, Case Reports, Analysis, Magazines, Editorials, Opinion, Communications, Mini-Review, Short Communications, Picturized, Book Review, Video type and Power Point Presentations (PPTS).

Journal of Immunology Research & Reports should be cover the topics related to Mineral Immunogenetics, Adaptive Immunity, Antigen Processing and Presentation, Antigen Recognition, Antimicrobial Responses, Applied Immunology, Autoimmune Diseases, Autoimmunity, Bone Marrow Transplantation, Cell Death and Immune Response, Chemokines, Gene Regulation in Immune Cells, HIV Immunity, Immune Cell Death, Immune Evasion, Lymphatic System, Mucosal Immunology, Tumor Immunity, Immunooncology, Genes and Immunity, Reproductive Processes, IntraVital, Nutrition and Cancer, Cogent Biology, Rare Diseases, Pathogens and Global Health, HIV Clinical Trials, Dermato-Endocrinology, Immunological Investigations, Immunological Communications, Alpha-Fetoprotein,Cytokines, Immunoregulation, Machine Learning, Plant Disease Apparently Healthy PersonsDetection, Malignant Tumors, Statistics, Pseudomonas Aeruginosa, Hydrogen-Rich Alkaline Water, Sepsis-Related Immunosuppression, HLADR expression, etc. 

Articles can be submitted through online from  http://www.onlinescientificresearch.com/submit-online.php  or can send through an e-mail with attachment for  [email protected]

Our Articles Indexed In

Journal Menu

Our Pubmed Indexed Articles

Detecting peripheral neuropathy in patients with diabetes, prediabetes and other high-risk conditions: an advanced practice nurse’s perspective, an analysis of peripheral neuropathy symptom characteristics in hiv, overview of neurotrauma and sensory loss.

Immunology Collaboration and Licensing Agreements Analysis Report 2024 with Directory of Deals Signed Since 2016 - Company A-Z, Therapy Focus and Technology Type

May 16, 2024 10:45 ET | Source: Research and Markets Research and Markets

Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Immunology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of immunology deals from 2016 to 2024. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners. The initial chapters of this report provide an orientation of immunology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in immunology dealmaking. Chapter 3 covers the financial deal terms for deals signed in the immunology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates. Chapter 4 provides a review of the top 25 most active biopharma companies in immunology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database. Chapter 5 provides a comprehensive and detailed review of immunology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive directory of immunology deals listed by therapeutic target. The report also includes numerous table and figures that illustrate the trends and activities in immunology deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Key Benefits

• Understand deal trends since 2016
• Browse immunology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in immunology dealmaking 2.1. Introduction 2.2. Immunology partnering over the years 2.3. Immunology partnering by deal type 2.4. Immunology partnering by industry sector 2.5. Immunology partnering by stage of development 2.6. Immunology partnering by technology type 2.7. Immunology partnering by therapeutic indication Chapter 3 - Financial deal terms for immunology partnering 3.1. Introduction 3.2. Disclosed financials terms for immunology partnering 3.3. Immunology partnering headline values 3.4. Immunology deal upfront payments 3.5. Immunology deal milestone payments 3.6. Immunology royalty rates Chapter 4 - Leading immunology deals and dealmakers 4.1. Introduction 4.2. Most active in immunology partnering 4.3. List of most active dealmakers in immunology 4.4. Top immunology deals by value Chapter 5 - Immunology contract document directory 5.1. Introduction 5.2. Immunology partnering deals where contract document available Chapter 6 - Immunology dealmaking by therapeutic target 6.1. Introduction 6.2. Deals by immunology therapeutic target Deal directory

• Deal directory - Immunology deals by company A-Z 2016 to 2024
• Deal directory - Immunology deals by technology type 2016 to 2024
• Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/u66c9g

About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Related Links

• Flow Cytometry in Oncology and Immunology Global Market Report 2024
• Allergy And Immunology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F
• Global Flow Cytometry in Oncology & Immunology Market by Type (Immunology, Oncology), Technology (Bead-based Flow Cytometry, Cell-based Flow Cytometry), Product & Service, End User - Forecast 2024-2030

Contact Data

• Get 7 Days Free

Johnson & Johnson

Johnson & johnson: proteologix acquisition yields promising early-stage immunology drugs.

Johnson & Johnson’s announced acquisition of Proteologix for $850 million upfront followed by potential milestone payments doesn’t impact our fair value estimate but yields attractive early-stage atopic dermatitis and asthma drugs at a reasonable price. The pipeline drugs complement J&J’s well-positioned immunology franchise and hold the potential to help strengthen the firm’s wide moat.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of JNJ so you can make buy / sell decisions free of market noise.

Sponsor Center

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals

Immune system articles from across Nature Portfolio

The immune system is a complex network of cells, tissues and organs that work together to protect the body from harmful substances and organisms and defend against disease. The immune system can be classified into distinct responses, such as innate immunity and adaptive immunity, or humoral immunity and cell-mediated immunity.

Related Subjects

• Dendritic cells
• Monocytes and macrophages

Latest Research and Reviews

Inhaled particulate accumulation with age impairs immune function and architecture in human lung lymph nodes

Carbon-containing particulates accumulate with age in a subset of macrophages in human lung-associated lymph nodes, decrease macrophage phagocytic capacity and turnover and disrupt lymphoid tissue structure, potentially compromising adaptive immune responses.

• Basak B. Ural
• Daniel P. Caron
• Donna L. Farber

Asplenia and spleen hypofunction

Asplenia and hyposplenism can have multiple and complex causes and lead to morbidity and mortality, especially owing to overwhelming post-splenectomy infections. In this Primer, Lenti and colleagues review epidemiology, pathophysiology, diagnosis and management of these conditions, and discuss patient quality of life and future strategies.

• Marco Vincenzo Lenti
• Antonio Di Sabatino

The human splenic microcirculation is entirely open as shown by 3D models in virtual reality

• Birte S. Steiniger
• Henriette Pfeffer
• Oleg Lobachev

Ascorbate maintains a low plasma oxygen level

• Louise Injarabian
• Marc Scherlinger
• Benoit S. Marteyn

T cell subsets and functions in atherosclerosis

Accumulating evidence supports the critical role of T cells as drivers and modifiers of atherosclerosis. In this Review, Ley and colleagues describe the latest advances in our understanding of the role of T cell subsets in atherosclerosis, discuss the process of T cell homing to atherosclerotic plaques and highlight potential T cell-related therapies for atherosclerosis.

• Ryosuke Saigusa
• Holger Winkels

Antimicrobial host defence peptides: functions and clinical potential

Naturally occurring cationic host defence peptides, also known as antimicrobial peptides, can control infections by their direct microbicidal properties and by modulating the host’s immune responses. In addition, certain cationic host defence peptides can resolve harmful inflammation. Here, Mookherjee et al. assess the emerging potential to therapeutically harness these peptides to treat infectious diseases, chronic inflammatory disorders and wound healing, highlighting current preclinical studies and clinical trials.

• Neeloffer Mookherjee
• Marilyn A. Anderson
• Donald J. Davidson

News and Comment

Rebalancing the aged immune system

• Hannah Walters

A T reg cell duo for VAT control

• Maria Papatriantafyllou

Eosinophils regulate bone remodelling

Results of a new study indicate that eosinophils have a role in maintaining bone homeostasis through their inhibitory effects on bone-resorbing osteoclasts.

• Sarah Onuora

Remembering T reg cells

• Stephanie Houston

Disrupting a cell-specific miRNA– CXCR4 interaction is atheroprotective in mice

An approach that increases the expression of the chemokine receptor CXCR4 in vascular cells by targeting a microRNA-based repressive pathway attenuates atherosclerosis in mice and promotes atheroprotective functions in human and mouse vascular cells in vitro.

• Irene Fernández-Ruiz

lnc(RNA)-ing myeloid metabolism

Quick links.

• Explore articles by subject
• Guide to authors
• Editorial policies